Key result
Molecular targeted anticancer drugs are linked to heart, liver, and lung damage.
Why the study?
Molecular targeted anticancer drugs cause organ toxicity and adverse effects that limit their clinical use, necessitating toxicology studies on their mechanisms and prevention.
What are the toxicities, related mechanisms, and preventive measures of molecular targeted anticancer drugs?
What are the toxicities, related mechanisms, and preventive measures of molecular targeted anticancer drugs?
Molecular targeted anticancer drugs can cause significant organ toxicity, necessitating further study into their mechanisms and preventive measures.
Answers are grounded in this paper and cite their sources.
May warrant monitoring for organ toxicities with targeted anticancer agents; leaves mechanisms and prevention strategies open for prospective study.
OBJECTIVE: Drug therapy is essential for cancer treatment. The molecular targeted anticancer drugs develop rapidly in recent years, since the effectiveness of traditional chemotherapy is unsatisfactory and the adverse reactions are high. However, molecular targeted anticancer drugs would damage the function of heart, liver or lung, and may cause adverse effects such as hand-foot syndrome, which restrains their clinical application. Therefore, it is critical for pharmaceutical toxicology to study the toxicity, the related mechanisms and the preventive measures of molecular targeted anticancer drugs.
No takes yet. Share an insight, caveat, or question.
Lou et al. (2015) conducted a review in Cancer. Molecular targeted anticancer drugs was evaluated. Molecular targeted anticancer drugs can cause adverse effects such as heart, liver, or lung damage and hand-foot syndrome, highlighting the need for further toxicological research.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: